Research before human studies

What is being studied

Researchers grew three-dimensional tissue spheres from human induced pluripotent stem cells, including myelin-producing oligodendrocytes and microglia. They induced myelin injury to study how human cells clear debris and form new myelin around nerve fibres, a process relevant to multiple sclerosis (MS).

Research stage

Not tested in people

Research so far is in laboratory cells or animal models.

What we know so far

The peer-reviewed paper reports myelin fragmentation, microglial uptake of debris, generation of new oligodendrocytes and new thinner myelin sheaths around axons. Remyelination was observed in only about half of differentiations. Developmental maturity is another limitation: stem-cell-derived models may not fully reflect adult tissue. This is evidence that the cell model reproduces selected repair processes. It does not reproduce every feature of adult MS and has no patient outcome.

What this means for patients today

No person with MS was treated in this study. The model may help future research and early screening of candidate compounds, but it is not a therapy, a clinical trial or proof of remyelination in patients. It creates no established treatment access in Greece.

What is being studied

Researchers tested K-9, a modified nucleoside that blocks an inflammation-related cell alarm, in a mouse model of MS. The experiments examined vision, movement, nerve cells and myelin.

Research stage

No clinical study in MS is established

For MS, findings are from animal models; the human K-9 eye-disease study does not establish a clinical study in MS.

What we know so far

The paper reports recovery of some existing vision and movement problems in mice and protection of nerve cells and myelin. This is animal evidence. Separate insurance analyses found associations involving other NRTI medicines; those are not studies of K-9 and do not show that K-9 works in people with MS. K-9 has also been studied in eye disease, which does not establish an MS study.

What this means for patients today

K-9 is not an MS treatment. No clinical study of K-9 for MS is established, and the animal findings do not show benefit in people.

What is being studied

Researchers combined two small molecules because together they increased myelin repair in experimental models. The combination is still at an early development stage.

Research stage

Not tested in people

Work remains in the laboratory and product development; a first safety study is planned.

What we know so far

The reported effect is from laboratory and animal models only. No benefit in people with MS has been shown.

What this means for patients today

This combination is not a treatment. More development and safety checks are needed before a human study could be considered.

What is being studied

Researchers are developing small molecules that activate mGluR5, a receptor involved in signalling that may influence myelin-making cells.

Research stage

Not tested in people

Research so far is in laboratory cells or animal models.

What we know so far

Activity has been reported in human myelin-making cells and animal models. The work remains at the laboratory-and-animal research stage; no benefit in people with MS is known.

What this means for patients today

These molecules are not treatments. A development partner and further work are still needed before human testing.

What is being studied

The team is refining a low-dose skin patch intended to deliver theophylline and affect HDAC2, a protein linked to myelin repair.

Research stage

Not tested in people

Work remains in the laboratory and product development; a first safety study is planned.

What we know so far

Current work concerns laboratory findings and patch development. A safety study in healthy volunteers is planned but has not been shown to have started.

What this means for patients today

This is early laboratory work, not a treatment for people with MS. A planned volunteer study would first address safety, not benefit in MS.

What is being studied

NeuOrphan presents Dioprotectome as a candidate for MS that is still at the laboratory-and-animal research stage. The available sources do not establish that Dioprotectome and DITPA are the same molecule. Separately, Monash studies DITPA, a compound related to thyroid hormones, for a possible role in myelin repair.

Research stage

No clinical study in MS is established

Research so far is in laboratory cells or animal models.

What we know so far

The Monash programme listing says this research is active through March 2028. Findings reported for DITPA are from laboratory and animal studies only. No established clinical study of DITPA in MS or proven benefit for people with MS is documented.

What this means for patients today

DITPA is not an available treatment for MS. The available sources do not establish a clinical study of DITPA for MS, so they do not show whether it benefits people with MS.

What is being studied

Researchers are investigating transplantation of neural stem cells created directly from other cells as a possible way to address long-term myelin loss.

Research stage

Not tested in people

Research so far is in laboratory cells or animal models.

What we know so far

Early findings suggest the approach may work in animal models of chronic myelin loss. This is not evidence of safety or benefit in people.

What this means for patients today

The cell approach has not been tested in people with MS. Delivery and safety questions remain before a human study could be considered.

What is being studied

Researchers modified human precursor cells so they can develop into myelin-making cells, then studied how the cells move toward chronic lesions.

Research stage

Not tested in people

Research so far is in laboratory cells or animal models.

What we know so far

In rodents, the cells moved toward long-term lesions and increased myelin repair. These animal findings do not establish safety or benefit in people.

What this means for patients today

This cell approach has not been tested in people with MS. Reliable manufacturing and long-term safety checks remain necessary.

What is being studied

CN045 is a small molecule intended to help immature cells mature into cells that make myelin. Researchers are refining it before considering human testing.

Research stage

Not tested in people

Research so far is in laboratory cells or animal models.

What we know so far

Promising effects have been reported in human cells studied in the laboratory and in mice. These findings do not show safety or benefit in people with MS.

What this means for patients today

CN045 is not a treatment. Further development and safety work are needed before a study in people could be considered.

What is being studied

Researchers are studying bavisant, which blocks the histamine H3 receptor, to see whether it can support myelin repair.

Research stage

Not tested in people

Research so far is in laboratory cells or animal models.

What we know so far

Effects have been reported in human cells and animal models. No study in people with MS is registered, so patient benefit is unknown.

What this means for patients today

This is early research, not a treatment people with MS can use. It has not been tested in patients.